CN100453650C - 预测免疫抑制治疗期间胆固醇升高的方法 - Google Patents

预测免疫抑制治疗期间胆固醇升高的方法 Download PDF

Info

Publication number
CN100453650C
CN100453650C CNB038233428A CN03823342A CN100453650C CN 100453650 C CN100453650 C CN 100453650C CN B038233428 A CNB038233428 A CN B038233428A CN 03823342 A CN03823342 A CN 03823342A CN 100453650 C CN100453650 C CN 100453650C
Authority
CN
China
Prior art keywords
gene
patient
cholesterol
haplotype
nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038233428A
Other languages
English (en)
Chinese (zh)
Other versions
CN1685062A (zh
Inventor
S·库达拉瓦利
M·H·波利梅罗普罗斯
R·托雷斯
C·D·沃尔夫冈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32043422&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100453650(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1685062A publication Critical patent/CN1685062A/zh
Application granted granted Critical
Publication of CN100453650C publication Critical patent/CN100453650C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNB038233428A 2002-09-30 2003-09-29 预测免疫抑制治疗期间胆固醇升高的方法 Expired - Fee Related CN100453650C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41512302P 2002-09-30 2002-09-30
US60/415,123 2002-09-30

Publications (2)

Publication Number Publication Date
CN1685062A CN1685062A (zh) 2005-10-19
CN100453650C true CN100453650C (zh) 2009-01-21

Family

ID=32043422

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038233428A Expired - Fee Related CN100453650C (zh) 2002-09-30 2003-09-29 预测免疫抑制治疗期间胆固醇升高的方法

Country Status (13)

Country Link
US (2) US7732134B2 (enExample)
EP (1) EP1549770B1 (enExample)
JP (1) JP4575775B2 (enExample)
CN (1) CN100453650C (enExample)
AT (1) ATE389034T1 (enExample)
AU (1) AU2003287955B2 (enExample)
BR (1) BR0314552A (enExample)
CA (1) CA2500979A1 (enExample)
DE (1) DE60319719T2 (enExample)
ES (1) ES2302959T3 (enExample)
IL (1) IL167639A (enExample)
PT (1) PT1549770E (enExample)
WO (1) WO2004029618A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007147600A (ru) * 2005-05-31 2009-07-20 Новартис АГ (CH) КОМБИНАЦИЯ ИНГИБИТОРОВ ГИДРОКСИ-МЕТИЛГЛУТАРИЛ-КОЭНЗИМ-А-РЕДУКТАЗЫ (ГМГ-КоА-РЕДУКТАЗЫ) И ИНГИБИТОРОВ МИШЕНИ РАПАМИЦИНА МЛЕКОПИТАЮЩИХ (МРМ)
JP2013509883A (ja) 2009-11-06 2013-03-21 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 臓器移植患者における移植片拒絶反応の非侵襲的診断方法
CA2793170C (en) * 2010-03-15 2018-04-17 Virginia Commonwealth University Aerosolized dapsone as a therapy for inflammation of the airway and abnormal mucociliary transport
US20130203769A1 (en) * 2012-02-08 2013-08-08 University Of Cincinnati Targeting Metabolic Adaptive Responses to Chemotherapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1194668A (zh) * 1996-04-05 1998-09-30 医疗科学系统有限公司 检测骨质疏松症的遗传素因
CN1198166A (zh) * 1995-08-03 1998-11-04 医疗科学系统有限公司 检测牙周病的遗传素因
US6268142B1 (en) * 1997-05-29 2001-07-31 Interleukin Genetics, Inc. Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6210877B1 (en) * 1997-03-10 2001-04-03 Interleukin Genetics, Inc. Prediction of coronary artery disease
US6524795B1 (en) * 1997-03-10 2003-02-25 Interleukin Genetics, Inc. Diagnostics for cardiovascular disorders
EP1463745A4 (en) * 2001-11-19 2007-11-07 Interleukin Genetics Inc FUNCTIONAL POLYMORPHISMS OF THE INTERLEUKIN-1 SITE AFFECTING TRANSCRIPTION AND SUSCEPTIBILITY TO INFLAMMATORY AND INFECTIOUS DISEASES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1198166A (zh) * 1995-08-03 1998-11-04 医疗科学系统有限公司 检测牙周病的遗传素因
CN1194668A (zh) * 1996-04-05 1998-09-30 医疗科学系统有限公司 检测骨质疏松症的遗传素因
US6268142B1 (en) * 1997-05-29 2001-07-31 Interleukin Genetics, Inc. Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Association of an interleukin 1B gene polymorphism (-511) with Parkinson's disease in Finnish patients. MATTILA K M ET AL.Journal of Medicine Genetics. 2002 *
Interleukin-1 polymorphisms associated within creased risk of gastric cancer. EL-OMAR E M ET AL.Nature,Vol.404. 2000 *
Singledose pharmacokinetics and tolerability of.......Van Damme-Lombaerts R,et al.Pediatr Transplant,Vol.6 No.2. 2002 *

Also Published As

Publication number Publication date
WO2004029618A2 (en) 2004-04-08
US20060246439A1 (en) 2006-11-02
BR0314552A (pt) 2005-08-09
JP4575775B2 (ja) 2010-11-04
ES2302959T3 (es) 2008-08-01
ATE389034T1 (de) 2008-03-15
AU2003287955B9 (en) 2004-04-19
WO2004029618A3 (en) 2004-06-17
PT1549770E (pt) 2008-06-24
CA2500979A1 (en) 2004-04-08
EP1549770B1 (en) 2008-03-12
US7732134B2 (en) 2010-06-08
IL167639A (en) 2011-10-31
HK1084445A1 (zh) 2006-07-28
AU2003287955B2 (en) 2007-06-21
DE60319719T2 (de) 2009-03-12
EP1549770A2 (en) 2005-07-06
US20100184798A1 (en) 2010-07-22
JP2006500930A (ja) 2006-01-12
DE60319719D1 (de) 2008-04-24
CN1685062A (zh) 2005-10-19
AU2003287955A1 (en) 2004-04-19

Similar Documents

Publication Publication Date Title
US20080166723A1 (en) CDK5 genetic markers associated with galantamine response
JP2012507297A (ja) Ｅｒｂｂ４遺伝子の多型に基づく精神病及び統合失調症の治療法
EP2041304B1 (en) Rgs2 genotypes associated with extrapyramidal symptoms induced by antipsychotic medication
US20100184798A1 (en) Methods to Predict Cholesterol Elevations during Immunosuppressant Therapy
US20050255488A1 (en) NTRK1 genetic markers associated with age of onset of Alzheimer's Disease
US20060166219A1 (en) NTRK1 genetic markers associated with progression of Alzheimer's disease
US20050250118A1 (en) EPHX2 Genetic markers associated with galantamine
US20050250121A1 (en) NTRK2 genetic markers associated with progression of Alzheimer's disease
US20050260613A1 (en) LRPAP1 genetic markers associated with galantamine
US20050048543A1 (en) CHRNA2 genetic markers associated with galantamine response
US20050250122A1 (en) APOA4 genetic markers associated with progression of Alzheimer's disease
US20050255492A1 (en) CHRNA9 genetic markers associated with progression of Alzheimer's disease
HK1084445B (en) Methods to predict cholesterol elevations during immunosuppressant therapy
WO2005059104A2 (en) Slc5a7 genetic markers associated with age of onset of alzheimer's disease
WO2005072150A2 (en) Ldlr genetic markers associated with age of onset of alzheimer's disease
OH et al. LINKAGE OF DOPAMINE RECEPTOR D2 (DRD2) MARKERS WITH ESSENTIAL HYPERTENSION IN SINGAPOREAN CHINESE SUBJECTS

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1084445

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1084445

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090121

Termination date: 20130929